Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06204679 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
A Phase 1 study, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT06204679: Completed Phase 1 study, sponsored by Atea Pharmaceuticals.
NCT06204679 is a Phase 1 study that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06204679, a Phase 1 study, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects
Primary Outcome
Maximum plasma concentration (Cmax)
Interventions
- DRUG Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions
- DRUG Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions
- DRUG Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2024-08-25 |
| Phase | Phase 1 |
What the finished NCT06204679 record still lists
NCT06204679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 3 interventions - of which Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions is the first listed.
NCT06204679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06204679 about?
NCT06204679 is a clinical study titled "Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir". This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects
What is the current status of trial NCT06204679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-12-14. Estimated completion is 2024-08-25.
What interventions are being tested in trial NCT06204679?
The interventions under investigation include: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions (DRUG), Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions (DRUG), Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions (DRUG).
Who is sponsoring clinical trial NCT06204679?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06204679's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI